We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




POC Diagnostic Platform Combines Immunoassay and Molecular Testing

By LabMedica International staff writers
Posted on 14 May 2025

An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design. More...

This platform not only demonstrates true lab-quality sensitivity, even with the most challenging clinical samples, but also maintains low invalid rates and minimal system downtime.

Cubit Diagnostics (Carlsbad, CA, USA) is further advancing the development of its integrated immunoassay and molecular benchtop analyzer, specifically designed for use in doctor’s offices and pharmacies, eliminating the need for multiple platforms and complicated testing workflows. The Cubit platform leverages a proprietary purification method and affordable microfluidic technologies to provide actionable results exactly when and where they are needed. By integrating cutting-edge target extraction technology with a simple, cost-effective design, CubitDx is addressing long-standing challenges in diagnostics. The result is laboratory-grade performance without sacrificing affordability, supporting the increasing trend of digital health and enabling more accessible care. The platform can simultaneously test up to 8 targets per run, offering comprehensive syndromic testing while performing both immunoassays and molecular testing on a single platform.

While initially focused on COVID-19, Flu A, and Flu B, the CubitDx platform is designed to tackle a wide range of critical health issues, including sepsis, sexually transmitted diseases (STDs), HIV, and HPV in the future. Evaluation results show that the CubitDx platform’s COVID-19 assay provides higher sensitivity than standard rapid tests and matches the sensitivity of large, high-throughput clinical laboratory systems. With the ability to deliver lab-quality results in just 15 minutes at the point of care, the platform aims to bring high-performance diagnostics closer to patients, improving both outcomes and accessibility worldwide. Offering affordable, high-sensitivity diagnostics for both resource-rich and cost-sensitive markets, the CubitDx platform has the potential to revolutionize healthcare access globally, from U.S. hospitals to underserved communities across Asia and Africa.

Related Links:
Cubit Diagnostics


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Hemoglobin Stool Test
CerTest FOB 50 + 200 One Step Combo Card Test
New
STI Test
REALQUALITY RQ-SevenSTI
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Schematic overview of the deep learning-based circulating exosome analysis for lung cancer detection (Photo courtesy of Chuan Xu, Cheng Jiang)

Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer

Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.